For proper segregation during cell division, each chromosome must connect to the poles of the spindle via microtubule bundles termed kinetochore fibers (K-fibers). K-fibers form by two distinct mechanisms: (1) capture of astral microtubules nucleated at the centrosome by the chromosomes’ kinetochores or (2) attachment of kinetochores to noncentrosomal microtubules with subsequent transport of the minus ends of these microtubules toward the spindle poles. The relative contributions of these alternative mechanisms to normal spindle assembly remain unknown. In this study, we report that most kinetochores in human cells develop K-fibers via the second mechanism. Correlative light electron microscopy demonstrates that from the onset of spindle assembly, short randomly oriented noncentrosomal microtubules appear in the immediate vicinity of the kinetochores. Initially, these microtubules interact with the kinetochores laterally, but end-on attachments form rapidly in the first 3 min of prometaphase. Conversion from lateral to end-on interactions is impeded upon inhibition of the plus end–directed kinetochore-associated kinesin CenpE.

HIV-1 Associated Neurocognitive Disorder (HAND) is a common and clinically detrimental complication of HIV infection. Viral proteins, including Tat, released from infected cells, cause neuronal toxicity. Substance abuse in HIV-infected patients greatly influences the severity of neuronal damage. To repurpose small molecule inhibitors for anti-HAND therapy, we employed MOLIERE, an AI-based literature mining system that we developed. All human genes were analyzed and prioritized by MOLIERE to find previously unknown targets connected to HAND. From the identified high priority genes, we narrowed the list to those with known small molecule ligands developed for other applications and lacking systemic toxicity in animal models. To validate the AI-based process, the selective small molecule inhibitor of DDX3 helicase activity, RK-33, was chosen and tested for neuroprotective activity. The compound, previously developed for cancer treatment, was tested for the prevention of combined neurotoxicity of HIV Tat and cocaine. Rodent cortical cultures were treated with 6 or 60 ng/ml of HIV Tat and 10 or 25 μM of cocaine, which caused substantial toxicity. RK-33 at doses as low as 1 μM greatly reduced the neurotoxicity of Tat and cocaine. Transcriptome analysis showed that most Tat-activated transcripts are microglia-specific genes and that RK-33 blocks their activation. Treatment with RK-33 inhibits the Tat and cocaine-dependent increase in the number and size of microglia and the proinflammatory cytokines IL-6, TNF-α, MCP-1/CCL2, MIP-2, IL-1α and IL-1β. These findings reveal that inhibition of DDX3 may have the potential to treat not only HAND but other neurodegenerative diseases. RK-33, selective inhibitor of Dead Box RNA helicase 3 (DDX3) protects neurons from combined Tat and cocaine neurotoxicity by inhibition of microglia activation and production of proinflammatory cytokines.

No pharmacotherapies exist to support muscle recovery from disuse. We developed particles for extended release of retinoic acid (ATRA-PLG) and investigated its impact on muscle recovery from cast immobilization. A single administration to the hindlimb, at the time of cast removal, accelerates soleus recovery and promotes macrophage polarization associated with repair. Our work supports ATRA-PLG as a clinical countermeasure to facilitate recovery from disuse and implicates modulation of inflammation as a mechanism of action.

Chemoresistance is a major obstacle in the treatment of triple negative breast cancer (TNBC), the most aggressive breast cancer subtype. To overcome chemoresistance, we have selected TNBC tumors for chemotherapy resistance in vivo, characterized their transcriptomes by RNA-sequencing and identified hypoxia-induced ECM re-modeler, lysyl oxidase (LOX) as a key inducer of chemoresistance. LOX overexpression has two distinct effects in hypoxic tumors treated with chemotherapy. As an ECM remodeler, LOX enhances collagen cross-linking and fibronectin assembly, thereby decreasing drug penetration. In addition, LOX exerts a surprising novel effect on transcription, increasing the expression of Integrin Subunit Alpha 5 (ITGA5), the major receptor for fibronectin (FN1), leading to activation of Focal Adhesion Kinase (FAK)/Src signaling and chemoresistance. Inhibition of LOX or ITGA5 with shRNA-mediated knockdown or inhibition of FAK or Src kinases with small molecule inhibitors in combination with doxorubicin greatly enhanced tumor growth inhibition in vivo relative to individual treatments. The role of LOX in chemoresistance has further been demonstrated using chemoresistant TNBC patient-derived xenografts (PDXs) and organoids, treated with doxorubicin alone or in combination with the LOX family inhibitor, BAPN. Notably, higher LOX, ITGA5, or FN1 levels are associated with shorter survival in chemotherapy treated TNBC patients. Currently available LOX inhibitors suffer from lack of specificity and high toxicity. To identify a more potent and selective LOX inhibitor, we performed a high-throughput screen (HTS) of a diversified small-molecule library. HTS resulted in identification of several hits that inhibit LOX enzymatic activity without any cytotoxicity. A lead compound was identified after the screening of hits based on their inhibitory effects on LOX enzymatic activity and the degree of chemosensitization in collagen-embedded cells. We are currently performing structure-activity relationship (SAR) analysis to optimize the lead compound for more potent activity and better drug-like properties. In addition, we are analyzing the mechanisms through which LOX enhances ITGA5 transcription and how the enzymatic activity of LOX contributes to transcriptional regulation. Our study provides a pre-clinical rationale for the development and testing of LOX inhibitors to overcome chemotherapy resistance in TNBC patients. Citation Format: Ozge Saatci, Ozge Akbulut, Abdol-Hossein Rezaeain, Carolyn Banister, Vitali Sikirzhytski, Sercan Aksoy, Aytekin Akyol, Aysegul Uner, Phillip Buckhaults, Mikhail Chernov, Campbell McInnes, Yasser Riazalhosseini, Ozgur Sahin. Overcoming chemotherapy resistance in triple negative breast cancer via targeting lysyl oxidase (LOX) [abstract]. In: Proceedings of the AACR Virtual Special Conference on the Evolving Tumor Microenvironment in Cancer Progression: Mechanisms and Emerging Therapeutic Opportunities; in association with the Tumor Microenvironment (TME) Working Group; 2021 Jan 11-12. Philadelphia (PA): AACR; Cancer Res 2021;81(5 Suppl):Abstract nr LT015.

Single particle tracking (SPT) is a powerful technique for probing the diverse physical properties of the cytoplasm. Genetically encoded nanoparticles provide an especially convenient tool for such investigations, as they can be expressed and tracked in cells via fluorescence. Among these, 40-nm GEMs provide a unique opportunity to explore the cytoplasm. Their size corresponds to that of ribosomes and big protein complexes, allowing us to investigate the effects of the cytoplasm on the diffusivity of these objects while excluding the influence of chemical interactions during stressful events and pathological conditions. However, it has been shown that cytoplasmic viscosity is tightly regulated and plays a crucial role in maintaining homeostasis during protein synthesis and degradation. Despite this, the effects of GEM expression levels on diffusivity remain largely uncharacterized in mammalian cells. To optimize the GEMs tracking and estimate GEMs-expression effects we constructed dox-inducible GEM expression system and compare with a previously reported constitutive expression system. The optimized level of GEMs expression increases the measured diffusivity from 0.29 ± 0.02 μm ² /sec in GEMs-overexpressed cells to 0.35 ± 0.02 μm ² /sec; improve homogeneity throughout the cell population; and facilitates particle tracking. We also improved the analyses of GEM diffusivity by applying effective diffusion coefficient while considering the type of motion and assessing the heterogeneity in the type of motion by calculating the standard deviations of particle displacements. Statement of significance: Describing cytoplasmic properties, such as environmental viscosity and protein complex motion, is essential for understanding molecular-level changes in cell function and pathology. A recently developed approach uses self-assembling fluorescent protein probes, expressed in cells, to investigate cytoplasmic properties through single-particle tracking (SPT). One such system employs genetically encoded multimeric (GEM) nanoparticles— scaffold protein structures similar in size to ribosomes. This study addresses a key limitation in SPT of GEMs by examining how varying GEM expression levels affect measured diffusivity and tracking quality in mammalian cells. Our findings demonstrate that controlled GEM expression reduces particle overcrowding, increases measured diffusivity, and enhances track detection. This work contributes valuable insights into optimizing GEM nanoparticle applications for studying cytoplasmic viscosity and motion dynamics.

HIV-associated neurological disorder (HAND) is a serious complication of HIV infection, marked by neurotoxicity induced by viral proteins like Tat. Substance abuse exacerbates neurocognitive impairment in people living with HIV. There is an urgent need for effective therapeutic strategies to combat HAND comorbid with Cocaine Use Disorder (CUD). Our analysis of the HIV and cocaine-induced transcriptomes in primary cortical cultures revealed a significant overexpression of the macrophage-specific gene, aconitate decarboxylase 1 (Acod1), caused by the combined insults of HIV and cocaine. ACOD1 protein converts the tricarboxylic acid intermediate cis-aconitate into itaconate during the activation of inflammation. The itaconate produced facilitates cytokine production and subsequently activates anti-inflammatory transcription factors, shielding macrophages from infection-induced cell death. While the role of itaconate’ in limiting inflammation has been studied in peripheral macrophages, its immunometabolic function remains unexplored in HIV and cocaine-exposed microglia. We assessed in this model system the potential of 4-octyl-itaconate (4OI), a cell-penetrable esterified form of itaconate known for its potent anti-inflammatory properties and potential therapeutic applications. We administered 4OI to primary cortical cultures exposed to Tat and cocaine. 4OI treatment increased the number of microglial cells in both untreated and Tat±Cocaine-treated cultures and also reversed the morphological altercations induced by Tat and cocaine. In the presence of 4OI, microglial cells also appeared more ramified, resembling the quiescent microglia. Consistent with these results, 4OI treatment inhibited the secretion of the proinflammatory cytokines IL-1α, IL-1β, IL-6, and MIP1-α induced by Tat and cocaine. Transcriptome profiling further determined that Nrf2 target genes such as NAD(P)H quinone oxidoreductase 1 (Nqo1), Glutathione S-transferase Pi (Gstp1), and glutamate cysteine ligase catalytic (Gclc), were most significantly activated in Tat-4OI treated cultures, relative to Tat alone. Further, genes associated with cytoskeleton dynamics in inflammatory microglia were downregulated by 4OI treatment. Together, the results strongly suggest 4-octyl-itaconate holds promise as a potential candidate for therapeutic development aimed at addressing HAND coupled with CUD comorbidities. Abstract Figure: Graphical Model of 4OI-mediated neuroprotection against Tat-Cocaine toxicity: Tat and Tat-Cocaine treatment induce neuronal damage, which is mitigated by 4OI through microglia cells. This cartoon shows the reduction of harmful effects such as proinflammatory cytokine release, upregulation of P2R, PDE, and Acod1 by the presence of 4OI. This ester modified itaconate triggers anti-inflammatory responses and activates antioxidant pathways.